Cross‐linking disulfide bonds govern solution structures of diabodies
暂无分享,去创建一个
K. Liedl | Franz Waibl | Monica L. Fernández-Quintero | L. M. Lamp | Barbara A. Math | Monica L. Fernández-Quintero
[1] A. Bujotzek,et al. OCD.py - Characterizing immunoglobulin inter-domain orientations , 2021, bioRxiv.
[2] E. Arnold,et al. Co-crystallization with diabodies: a case study for the introduction of synthetic symmetry. , 2021, Structure.
[3] F. Forneris,et al. Inference of molecular structure for characterization and improvement of clinical grade immunocytokines. , 2021, Journal of structural biology.
[4] Patrick K. Quoika,et al. Surprisingly Fast Interface and Elbow Angle Dynamics of Antigen-Binding Fragments , 2020, Frontiers in Molecular Biosciences.
[5] A. Bujotzek,et al. Antibodies exhibit multiple paratope states influencing VH–VL domain orientations , 2020, Communications Biology.
[6] Yoshikazu Tanaka,et al. Association behavior and control of the quality of cancer therapeutic bispecific diabodies expressed in Escherichia coli , 2020 .
[7] K. Liedl,et al. T-Cell Receptor CDR3 Loop Conformations in Solution Shift the Relative Vα-Vβ Domain Distributions , 2020, Frontiers in Immunology.
[8] Jaime Fern'andez del R'io,et al. Array programming with NumPy , 2020, Nature.
[9] I. Sassoon,et al. Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations , 2020, SLAS discovery : advancing life sciences R & D.
[10] A. Bujotzek,et al. VH‐VL interdomain dynamics observed by computer simulations and NMR , 2020, Proteins.
[11] K. Liedl,et al. Antibody CDR loops as ensembles in solution vs. canonical clusters from X-ray structures , 2020, mAbs.
[12] J. Reichert,et al. Antibodies to watch in 2020 , 2019, mAbs.
[13] K. Liedl,et al. Transitions of CDR-L3 Loop Canonical Cluster Conformations on the Micro-to-Millisecond Timescale , 2019, Front. Immunol..
[14] T. Hellweg,et al. Distinguishing Between Monomeric scFv and Diabody in Solution Using Light and Small Angle X-ray Scattering , 2019, Antibodies.
[15] Jakub Rydzewski,et al. Promoting transparency and reproducibility in enhanced molecular simulations , 2019, Nature Methods.
[16] Johannes L. Schönberger,et al. SciPy 1.0: fundamental algorithms for scientific computing in Python , 2019, Nature Methods.
[17] Janice M Reichert,et al. Bispecific antibodies: a mechanistic review of the pipeline , 2019, Nature Reviews Drug Discovery.
[18] R. Kontermann,et al. Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules , 2019, mAbs.
[19] Jie-Oh Lee,et al. Structural diversity and flexibility of diabodies. , 2019, Methods.
[20] K. Liedl,et al. Characterizing the Diversity of the CDR-H3 Loop Conformational Ensembles in Relationship to Antibody Binding Properties , 2019, Front. Immunol..
[21] Daniel A. Richards,et al. Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery. , 2018, Drug discovery today. Technologies.
[22] Hayyoung Lee,et al. Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface , 2016, Scientific Reports.
[23] Jeffrey J. Gray,et al. Large-scale sequence and structural comparisons of human naive and antigen-experienced antibody repertoires , 2016, Proceedings of the National Academy of Sciences.
[24] James R. Apgar,et al. Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer , 2016, Antibodies.
[25] Thomas J Lane,et al. MDTraj: a modern, open library for the analysis of molecular dynamics trajectories , 2014, bioRxiv.
[26] Frank Noé,et al. PyEMMA 2: A Software Package for Estimation, Validation, and Analysis of Markov Models. , 2015, Journal of chemical theory and computation.
[27] C. Simmerling,et al. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.
[28] James Dunbar,et al. Prediction of VH–VL domain orientation for antibody variable domain modeling , 2015, Proteins.
[29] Irving L. Weissman,et al. Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands , 2015, Cell.
[30] Brian D. Weitzner,et al. The origin of CDR H3 structural diversity. , 2015, Structure.
[31] Massimiliano Bonomi,et al. PLUMED 2: New feathers for an old bird , 2013, Comput. Phys. Commun..
[32] C. Deane,et al. ABangle: characterising the VH-VL orientation in antibodies. , 2013, Protein engineering, design & selection : PEDS.
[33] Duncan Poole,et al. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. , 2013, Journal of chemical theory and computation.
[34] P. Baeuerle,et al. Targeting T cells to tumor cells using bispecific antibodies. , 2013, Current opinion in chemical biology.
[35] P. Kufer,et al. Blinatumomab: a historical perspective. , 2012, Pharmacology & therapeutics.
[36] L. Possani,et al. A single mutation in framework 2 of the heavy variable domain improves the properties of a diabody and a related single-chain antibody. , 2012, Journal of molecular biology.
[37] Andreas Wolf,et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. , 2012, Blood.
[38] Haruki Nakamura,et al. Computer-aided antibody design , 2012, Protein engineering, design & selection : PEDS.
[39] Robert L. Jernigan,et al. Protein Loop Dynamics Are Complex and Depend on the Motions of the Whole Protein , 2012, Entropy.
[40] Hiroki Hayashi,et al. Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system , 2012, The FEBS journal.
[41] Hermann Einsele,et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Klaus R. Liedl,et al. A challenging system: Free energy prediction for factor Xa , 2011, J. Comput. Chem..
[43] C. Rader. DARTs take aim at BiTEs. , 2011, Blood.
[44] P. Moore,et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. , 2011, Blood.
[45] Roland L. Dunbrack,et al. A new clustering of antibody CDR loop conformations. , 2011, Journal of molecular biology.
[46] Andrew C. R. Martin,et al. Analysis and prediction of VH/VL packing in antibodies. , 2010, Protein engineering, design & selection : PEDS.
[47] Thomas Singer,et al. The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.
[48] R. Kontermann. Alternative antibody formats. , 2010, Current opinion in molecular therapeutics.
[49] Etienne Weiss,et al. Therapeutic antibodies: successes, limitations and hopes for the future , 2009, British journal of pharmacology.
[50] Massimiliano Bonomi,et al. PLUMED: A portable plugin for free-energy calculations with molecular dynamics , 2009, Comput. Phys. Commun..
[51] P. Labute. proteins STRUCTURE O FUNCTION O BIOINFORMATICS Protonate3D: Assignment of ionization , 2013 .
[52] A. Plückthun,et al. Structure of the recombinant antibody Fab fragment f3p4. , 2008, Acta crystallographica. Section D, Biological crystallography.
[53] M. Parrinello,et al. Well-tempered metadynamics: a smoothly converging and tunable free-energy method. , 2008, Physical review letters.
[54] D. Kern,et al. Dynamic personalities of proteins , 2007, Nature.
[55] Michael Andrec,et al. A large data set comparison of protein structures determined by crystallography and NMR: Statistical test for structural differences and the effect of crystal packing , 2007, Proteins.
[56] U. Wetterauer,et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells , 2007, Cancer Immunology, Immunotherapy.
[57] John D. Hunter,et al. Matplotlib: A 2D Graphics Environment , 2007, Computing in Science & Engineering.
[58] A. Laio,et al. A bias-exchange approach to protein folding. , 2007, The journal of physical chemistry. B.
[59] P. Hoffmann,et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. , 2007, Molecular immunology.
[60] A. Zemla,et al. Antibody elbow angles are influenced by their light chain class. , 2006, Journal of molecular biology.
[61] Marvin Edelman,et al. The limit of accuracy of protein modeling: influence of crystal packing on protein structure. , 2005, Journal of molecular biology.
[62] C. Rapp,et al. Crystal packing effects on protein loops , 2005, Proteins.
[63] J. Skolnick,et al. TM-align: a protein structure alignment algorithm based on the TM-score , 2005, Nucleic acids research.
[64] T. L. Brown,et al. TransMabs: cell-penetrating antibodies, the next generation , 2005, Expert opinion on biological therapy.
[65] Dan Lu,et al. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. , 2004, Biochemical and biophysical research communications.
[66] P. Kufer,et al. A revival of bispecific antibodies. , 2004, Trends in biotechnology.
[67] M. Little,et al. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. , 2004, Protein engineering, design & selection : PEDS.
[68] A. Wu,et al. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. , 2003, Journal of molecular biology.
[69] B. Alberts,et al. Molecular Biology of the Cell (4th Ed) , 2002 .
[70] P. Carter,et al. Bispecific human IgG by design. , 2001, Journal of immunological methods.
[71] Guido Rossum,et al. Python Reference Manual , 2000 .
[72] B. Rode,et al. Elbow flexibility and ligand-induced domain rearrangements in antibody Fab NC6.8: large effects of a small hapten. , 2000, Biophysical journal.
[73] P. Bohlen,et al. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. , 1999, Journal of immunological methods.
[74] M. Little,et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. , 1999, Journal of molecular biology.
[75] Michaela A. E. Arndt,et al. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. , 1999, Blood.
[76] E. Eliopoulos,et al. Construction and characterization of a humanized single chain Fv antibody fragment against the main immunogenic region of the acetylcholine receptor , 1999, Journal of Neuroimmunology.
[77] B. Rode,et al. Ligand-induced domain movement in an antibody Fab: molecular dynamics studies confirm the unique domain movement observed experimentally for Fab NC6.8 upon complexation and reveal its segmental flexibility. , 1998, Journal of molecular biology.
[78] P. Iliades,et al. Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments , 1998, FEBS letters.
[79] A. Lesk,et al. Standard conformations for the canonical structures of immunoglobulins. , 1997, Journal of molecular biology.
[80] A. George,et al. Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. , 1997, Journal of immunological methods.
[81] M. Bott. Anaerobic citrate metabolism and its regulation in enterobacteria , 1997, Archives of Microbiology.
[82] B. Snedecor,et al. High Level Secretion of a Humanized Bispecific Diabody from Escherichia coli , 1996, Bio/Technology.
[83] Payne,et al. Periodic boundary conditions in ab initio calculations. , 1995, Physical review. B, Condensed matter.
[84] R. Williams,et al. Crystal structure of a diabody, a bivalent antibody fragment. , 1994, Structure.
[85] T Prospero,et al. "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[86] T. Darden,et al. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .
[87] P. Chavrier,et al. Molecular Biology of the Cell , 1990, Color Atlas of Clinical Hematology.
[88] A. Lesk,et al. Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.
[89] H. Berendsen,et al. Molecular dynamics with coupling to an external bath , 1984 .
[90] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[91] T. Schneider,et al. Molecular-dynamics study of a three-dimensional one-component model for distortive phase transitions , 1978 .
[92] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .
[93] R. Porter. Separation and Isolation of Fractions of Rabbit Gamma-Globulin containing the Antibody and Antigenic Combining Sites , 1958, Nature.
[94] Guy Georges,et al. The intriguing options of multispecific antibody formats for treatment of cancer. , 2013, Cancer genomics & proteomics.
[95] Alessandro Laio,et al. Protein Folding and Ligand-Enzyme Binding from Bias-Exchange Metadynamics Simulations , 2012 .
[96] Massimiliano Bonomi,et al. Metadynamics , 2019, ioChem-BD Computational Chemistry Datasets.
[97] A. Steinacker,et al. A Spice Study of Silicon Sensor Strip Noise on Long Ladders , 2011 .
[98] R. Kontermann. Recombinant bispecific antibodies for cancer therapy , 2005, Acta Pharmacologica Sinica.
[99] RolandEKONTERMANN. Recombinant bispecific antibodies for cancer therapy , 2005 .
[100] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[101] E. Kabat,et al. Sequences of proteins of immunological interest , 1991 .
[102] Brian D. Weitzner,et al. The Origin of CDR H 3 Structural Diversity , 2022 .